-
Mashup Score: 5FDA approves NMIBC treatment nogapendekin alfa-inbakicept/BCG - 28 day(s) ago
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Bladder cancer study to develop predictive model for response to BCG - 3 month(s) ago
A personalized patient genetic index will be created to show the presence of bladder cancer as well as evaluate patient response to BCG immunotherapy,” says Marvin S. Hausman, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Dr. Lyon on a phase 2 study of in-home treatment for NMIBC - 5 month(s) ago
“The primary outcome will be feasibility of in-home treatments,” says Timothy D. Lyon, MD, FACS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 16Dr. Lyon on in-home intravesical therapy in bladder cancer - 5 month(s) ago
“We were pleased and excited to see that 72% of patients reported openness to receiving in-home intravesical therapy,” says Timothy D. Lyon, MD, FACS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
FDA approves NMIBC treatment nogapendekin alfa-inbakicept/BCG https://t.co/3PFKXX2Wel #urology #urologist #bladdercancer